Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
The EyePoint, Inc. (EYPT) news page on Stock Titan aggregates company-reported updates and market-moving announcements for this clinical-stage biopharmaceutical business focused on serious retinal diseases. EyePoint’s disclosures emphasize its lead investigational product, DURAVYU™ (vorolanib intravitreal insert), and its progress through late-stage clinical development, making corporate news particularly relevant for investors tracking ophthalmology and retinal therapeutics.
Visitors can review news covering clinical milestones, such as enrollment completion and data safety monitoring committee recommendations for the Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration (wet AMD), as well as the design and initiation of the pivotal Phase 3 COMO and CAPRI trials in diabetic macular edema (DME). Company releases also highlight Phase 2 data from the DAVIO 2 and VERONA studies, which EyePoint cites as demonstrating meaningful and sustained improvements in vision and anatomy with favorable safety profiles.
In addition to clinical trial updates, EyePoint’s news includes financing and corporate developments, such as underwritten public offerings, at-the-market equity programs, and inducement grants under Nasdaq Listing Rule 5635(c)(4). These items provide context on how the company funds its DURAVYU programs and earlier-stage pipeline initiatives. Investors can also follow announcements about conference presentations at major healthcare and ophthalmology meetings and investor conferences, where EyePoint discusses its clinical data, trial designs, and development strategy.
By monitoring the EYPT news feed, readers can see how EyePoint communicates progress on its investigational sustained-delivery approach, interactions with regulators, and key risk disclosures referenced in forward-looking statements. This page is useful for those who want a centralized view of EyePoint’s official announcements, ranging from clinical milestones and safety updates to capital-raising activities and corporate governance events.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its participation in three upcoming investor conferences in June 2025:
- Jefferies Global Healthcare Conference on June 4 at 1:25 p.m. ET
- Goldman Sachs 46th Annual Global Healthcare Conference on June 10 at 2:40 p.m. ET
- Guggenheim BioFrontier Boston Event on June 25 at 4:00 p.m. ET
The company will participate in fireside chats at each event, with live webcasts and archived replays available through EyePoint's investor relations website.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to seven new employees as inducement awards. The grants, approved by the Compensation Committee on May 15, 2025, include options to purchase up to 136,700 shares of EyePoint common stock at an exercise price of $5.72 per share. These options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments over the following three years. The inducement awards were granted outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
EyePoint Pharmaceuticals (NASDAQ: EYPT), a pharmaceutical company focused on developing treatments for serious retinal diseases, has announced its participation in three upcoming investor conferences in May 2025:
- RBC Capital Markets Global Healthcare Conference: Fireside chat on May 20 at 10:00 a.m. ET
- Mizuho Neuro & Ophthalmology Summit: One-on-one meetings on May 21
- Stifel Virtual Ophthalmology Forum: Fireside chat on May 27 at 8:30 a.m. ET
Investors can access live webcasts and replays of the presentations through EyePoint's website investor section.
EyePoint Pharmaceuticals (EYPT) reported strong progress in Q1 2025, with their Phase 3 DURAVYU trials for wet AMD showing exceptional enrollment rates. The LUGANO trial has reached over 90% enrollment and LUCIA over 50%, with both expected to complete enrollment in 2H 2025. The company reported total net revenue of $24.5 million, up from $11.7 million in Q1 2024, primarily driven by YUTIQ licensing revenue.
The company maintains a strong financial position with $318.2 million in cash and equivalents, providing runway into 2027. Operating expenses increased to $73.3 million, mainly due to accelerated trial enrollment. Net loss was $45.2 million ($0.65 per share). DURAVYU demonstrated promising results in Phase 2 VERONA trial for diabetic macular edema, showing significant vision improvement and fluid reduction compared to aflibercept control.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a pharmaceutical company focused on developing innovative therapeutics for serious retinal diseases, has scheduled its first quarter 2025 financial results announcement for May 7, 2025.
The company will host a conference call and live webcast at 8:30 a.m. ET to discuss Q1 2025 financial performance and recent corporate developments. Interested participants can register for the audio conference through a provided link, while a live webcast will be accessible through the Investors section of EyePoint's website. A replay of the webcast will be made available on the corporate website after the call concludes.
EyePoint Pharmaceuticals (EYPT) has granted non-statutory stock options to four new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The grants, approved by the Compensation Committee on April 15, 2025, allow the purchase of up to 65,000 shares of EyePoint common stock at an exercise price of $5.67 per share.
The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first anniversary, with the remaining shares vesting in equal monthly installments over the following three years. Vesting is contingent upon continued employment with EyePoint through the applicable dates.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a leading developer of therapeutics for serious retinal diseases, has announced its upcoming participation in the 2025 RBC Capital Markets Ophthalmology Virtual Conference.
The company's President and CEO, Jay S. Duker, M.D., will engage in a fireside chat scheduled for April 4, 2025, at 10:00 a.m. ET. Investors and interested parties can access the live webcast and subsequent replay through the Investors section on EyePoint's website at www.eyepointpharma.com.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced the granting of non-statutory stock options to four new employees as inducement awards. The grants, approved by the Compensation Committee on March 14, 2025, include options to purchase up to 34,500 shares of common stock at an exercise price of $6.52 per share.
The stock options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first anniversary, with the remaining amount vesting in equal monthly installments over the following three years. The vesting is contingent upon continued employment with EyePoint Pharmaceuticals.